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Given the recent in vitro discovery that the free soluble oligosaccharide of GM1 is the bioactive portion 
of GM1 for neurotrophic functions, we investigated its therapeutic potential in the B4galnt1+/− mice, 
a model of sporadic Parkinson’s disease. We found that the GM1 oligosaccharide, systemically 
administered, reaches the brain and completely rescues the physical symptoms, reduces the 
abnormal nigral α-synuclein content, restores nigral tyrosine hydroxylase expression and striatal 
neurotransmitter levels, overlapping the wild-type condition. Thus, this study supports the idea that 
the Parkinson’s phenotype expressed by the B4galnt1+/− mice is due to a reduced level of neuronal 
ganglioside content and lack of interactions between the oligosaccharide portion of GM1 with specific 
membrane proteins. It also points to the therapeutic potential of the GM1 oligosaccharide for treatment 
of sporadic Parkinson’s disease.
Gangliosides are key components of the neuronal plasma membranes1–6, where they participate to determine the 
membrane organization and to modulate protein functions, in many cases by interacting with their oligosaccha-
ride moiety. Over the course of physiological aging, the ganglioside metabolic pathways (especially that of GM1) 
undergo progressive decline due to reduction of membrane ganglioside content and composition7,8, which can 
lead to progressive neurological dysfunction.
Accumulating evidence is pointing to a central role for subnormal levels of gangliosides as putative initiators 
of sporadic Parkinson’s disease (sPD) pathogenesis9–12. sPD patients present a reduction of GM1 ganglioside in 
the substantia nigra9, in the occipital cortex13 and various peripheral tissues, suggesting a GM1 systemic defi-
ciency that would correlate with the systemic symptoms of sPD12. In neuromelanin-containing neurons in the 
sPD substantia nigra the reduced ganglioside content is accompanied by a significant deficient expression in 
two genes involved in ganglioside synthesis: B3GALT4 and ST3GAL210. Several neuronal functions can become 
gradually compromised as the membrane GM1 content diminishes below a certain threshold with aging14 and/
or under epigenetic influences. In particular, it has been hypothesized that the reduced level of plasma mem-
brane GM1 in PD neurons can trigger the neurodegenerative process by a failure in neurotrophic signaling (i.e. 
GDNF)13 together with a reduction of GM1 interaction with α-synuclein (α-syn) that prevents aggregation of 
the latter12,15,16. Accordingly, as the population continues to age with a progressive decline of a-series gangliosides 
(GM1 and GD1a, its metabolic precursor, via plasma membrane bound sialidase Neu3), it can be expected that 
the number and percentage of persons developing sPD will multiply.
GM1 replacement therapy has shown modest but significant success in a monocentric controlled, delayed 
start trial in treated sPD patients17, acting as symptomatic and potentially disease modifier, since a partial res-
toration of dopamine (DA) transporter functional level in the striatum of GM1-treated subjects was reported18. 
Despite these suggestive positive evidences, the use of GM1 in clinical trials is severely hampered due to its low 
capacity to reach brain neurons. Gangliosides are amphiphilic compounds and in water solutions form micellar 
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aggregates displaying very low aggregation concentration. The critical micellar concentration of GM1 is about 
10−9 M19. Thus independently by the ganglioside concentration, the monomer concentration cannot be over 10−9 
M. Only monomers are capable to insert into the cell membranes20,21 using their lipid moiety, the ceramide. 
Accordingly, a very minor quantity of injected GM1 overcomes the blood brain barrier and reaches the neurons. 
Thus to obtain a therapeutic effect, GM1 is injected in great amount increasing the possibility to inject significant 
amounts of contaminants22,23. The risk of GM1 protein contamination, due to its animal origin, and the com-
pletely disproved, but still discussed, relationship with Guillain-Barre syndrome24–27 inhibit serious consideration 
of GM1 therapeutic use.
The consequences of partial removal of GM1 and the more complex gangliosides, obtained from the heterozy-
gous disruption of the B4galnt1 gene (GM2/GD2 synthase), was a condition sufficient for these mice to develop 
PD phenotype: α-syn elevation and aggregation within central (CNS) and peripheral nervous (PNS) lesions, 
striatal degeneration and growing motor dysfunction6,9,12,28,29. Interestingly, B4galnt1+/− mice subjected to GM1 
replacement therapy by administration of semi-synthetic and brain-permeable GM1 derivative coded LIGA20 
(with a dichloroacetyl group linked to the sphingosine amino group instead of the acyl chain) showed reversal of 
the pathological phenotype9. This result suggests that specific plasma membrane oligosaccharide–protein trig-
gered pathways are required for the correct neuronal homeostasis.
Many studies on GM1 neurotrophic properties have been carried out using in vitro culture of neuroblastoma 
and pheochromocytoma cell lines, which differentiate into neuron like cells following GM1 exogenous admin-
istration30–33. The differentiative properties of GM1 have been associated to its monomeric insertion into the 
plasma membrane and to its interaction/modulation with membrane protein receptors, such as TrkA and RET, 
membrane ion channels and integrins11,12,34.
We recently reported that the soluble GM1 oligosaccharide administered to neuroblastoma cells replicates the 
neurotrophic and neuroprotective properties of the GM1 ganglioside35–37. The GM1 oligosaccharide added to the 
cell culture medium activates the TrkA auto-phosphorylation followed by the downstream MAPK signaling35–37. 
Molecular modelling suggested the formation of a very stable trimeric complex between GM1 oligosaccharide, 
TrkA and NGF35.
In this paper, we describe the results obtained by administering the soluble oligosaccharide of ganglioside 
GM1 to the heterozygous B4galnt1+/− mouse, animal model of PD. During 4 weeks of oligosaccharide systemic 
administration, animals showed reversal of motor impairment, reduction of the aberrant levels of α-syn in the 
substantia nigra pars compacta (SNpc), recovery of nigral tyrosine hydroxylase (TH) expression and striatal DA 
level. These results are in favor of the development of a new human therapy of PD based on the administration of 
the GM1 soluble oligosaccharide.
Results
Identification of the [3H]OligoGM1 in the brain of treated WT mice. To understand if the OligoGM1 
could reach the CNS, we administered [3H]OligoGM1 to wild-type (WT) mice. Mice were intraperitoneally (IP) 
injected with [3H]OligoGM1 (20 mg/kg plus 13 × 106 dmp) and, 24 h following injection, brains were submitted 
to water soluble compounds and analyzed for the radioactivity and tritium labeled oligosaccharide contents. As 
shown in Fig. 1A, about 20% (±3.25 × 106 dpm) of the total injected radioactivity (1.3 × 107 dpm) was found 
associated to the brain. As reported (Fig. S1 of Supplementary) the large amount of radioactivity associated to 
the brain was non-volatile radioactivity, meaning that it is not associated to tritiated water generating upon the 
saccharide catabolism but rather it is associated to [3H]OligoGM1.
To further verify that the radioactivity was indeed corresponding to intact OligoGM1, we verify its meta-
bolic stability by high-performance thin-layer chromatography (HPTLC) autoradiography using a BetaIMAGER 
TRACER system (Biospace lab) and visualized using M3 vision software. As shown in Fig. 1B, metabolically stable 
[3H]OligoGM1 was found in the brain. No other radioactive compounds were identified considering that the 
detection limit of the instrument (BetaIMAGER TRACER system, Biospace lab) is 15 spotted dpm.
Restored motor activity in B4galnt1+/− mice treated with OligoGM1. OligoGM1 (20 mg/Kg) was 
daily IP injected to B4galnt1+/− mice for 4 weeks. To evaluate its effect on motor coordination, balance and 
fine motor movement, grip duration and irritant removal tests were assessed weekly9,13,28. Before starting the 
treatments, the physical impairment of animals was tested to record the basal state for both “grip” and “irritant 
removal” tests, in comparison with WT animals (Figs. 2 and 3). The graphs depicted in Fig. 2 and in Fig. 3 clearly 
show a significant recovery in motor behavior of B4galnt1+/− treated mice. Moreover, mice were tested with pole 
climbing for motor coordination and balance (Fig. 4) but only at the end of treatment to avoid that the learning 
ability could influence the success of the test. Figures 2–4 show that the treated B4galnt1+/− mice rapidly recov-
ered motor functions, some of them immediately after the first week of injections. OligoGM1 treated PD animals 
showed motor functions comparable with those of WT animals following 4 weeks of daily treatment. No signifi-
cant difference was found between male and female mice in response to the treatment (Fig. S2 of Supplementary).
Reduction in a-series gangliosides in B4galnt1+/− mice. Following the 4 weeks of treatment, the gan-
glioside pattern and content in mice brain cortex and cerebellum were analyzed following brain lipid extraction, 
ganglioside purification, ganglioside separation by HPTLC and ganglioside revelation by colorimetric detec-
tion39–41. WT and B4galnt1+/− mice treated with balanced saline solution (BSS), and B4galnt1+/− treated with the 
OligoGM1 were analyzed.
The B4galnt1+/− mouse brains had reduced amount of GM1 and GD1a with respect to WTs in both brain 
regions examined (Fig. 5). In parallel, we found a fair accumulation of GD3 in cerebellum and cerebral cortex 
of B4galnt1+/− mice with respect to WTs (Fig. 5). With the exception of GD1b, which was elevated in the cortex 
of B4galnt1+/− mice, the content of b-series gangliosides was not affected, suggesting that the amount of GD3 
3Scientific RepoRtS |         (2019) 9:19330  | https://doi.org/10.1038/s41598-019-55885-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
ganglioside available results in an optimal substrate level for the galactosaminyl transferase. No differences in 
ganglioside pattern and content were found in the brain of B4galnt1+/− animals treated for 4 weeks with saline 
solution or OligoGM1, indicating that the treatment is not capable to act on the metabolic pathway of ganglio-
sides (Fig. S3 of Supplementary).
These results confirm the reduction of gangliosides GM1 and GD1a in the B4galnt1+/− brain mice9 and show 
that the recovery of motor functions in B4galnt1+/− animals following oligosaccharide treatment was not associ-
ated to recovery of gangliosides GM1 and GD1a expression, due to activation of residual galactosaminyl trans-
ferase enzyme.
Reduction of the aberrant α-syn content in the SNpc of B4galnt1+/− mice treated with 
OligoGM1. A key feature of the B4galnt1+/− mice was marked elevation of α-syn in the SNpc9. To understand 
if the restored motor activity was accompanied by biochemical rescue of α-syn physiological levels, we performed 
fluorescent immunohistochemistry (IHC) analysis of nigral α-syn. We confirmed the increased content of α-syn 
in the B4galnt1+/− mice (Fig. 6), reproducing what was previously reported9. Interestingly, the OligoGM1 treated 
B4galnt1+/− mice were found with significantly reduced levels of α-syn overall reaching the WT situation (Fig. 6). 
Although we did not quantify the level of Ser129-phosphorylated α-syn, we found by IHC the positivity of 
α-syn to the Ser129-phosphorylation in the untreated B4galnt1+/− mice at the level of SNpc (Fig. S4, panel A of 
Supplementary). Importantly, the positive signal was less intense in the OligoGM1 treated B4galnt1+/− and, as 
expected, in WT mice (Fig. S4, panel A of Supplementary). Finally, immunoblotting analysis showed levels of 
Ser129-phosphorylated α-syn in OligoGM1 treated animals similar to those of WT mice, and lower compared to 
saline-treated animals (Fig. S4, panel B of Supplementary).
Recovery of the TH expression in the SNpc substantia nigra of B4galnt1+/− mice treated with 
OligoGM1. It has been reported that the B4galnt1 heterozygous disruption causes the degeneration of TH 
expressing neurons within the SNpc as well as the reduction of TH expression level9. To verify if OligoGM1 could 
restore the TH expression, we performed fluorescent IHC analysis on SNpc. As previously reported9, we found a 
decrease level of TH expression in B4galnt1+/− mice, which was rescued by OligoGM1 treatment, with restoration 
to WT levels (Fig. 7A). Additionally, immunoblotting evaluation confirmed a significant recovery of nigral TH 
expression in B4galnt1+/− mice treated with OligoGM1 compared to the WT level (Fig. 7B).
Figure 1. OligoGM1 penetrates into the brain. (A) Radioactivity associated to the brain mouse after injection 
of 1.3 × 107 dpm [3H]OligoGM1. Data are expressed as mean ± SEM of five independent experiments (n = 5). 
(B) Representative image of the HPTLC separation of the radioactive material contained in the brain (n = 5). 
Lane 1: standard [3H]OligoGM1; Lane 2: soluble extract from brain homogenate derived from [3H]OligoGM1 
injected mouse (24 h). Result is representative of those obtained for all the animals analyzed. HPTLC plates were 
developed with chloroform/methanol/0.2% CaCl2, 30:50:13 by vol. Tritium was detected with Beta-Imager 2000 
instrument (Biospace) using an acquisition time of 16 h.
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Restoration of striatal neurotransmitter levels in B4galnt1+/− mice treated with OligoGM1. 
The homozygous B4galnt1−/− mice were previously found to have decreased levels of DA as well as its metabolite, 
3,4-dihydroxyphenylacetic acid (DOPAC), in the striatum28. Thus, in order to further validate our findings and 
to determine whether the OligoGM1 could rescue the pathological phenotype by promoting the synthesis of 
striatal neurotransmitters, we performed neurochemical analysis with electrochemical detection high perfor-
mance liquid chromatography (ED-HPLC). We confirmed that striatal levels of DA, DOPAC and norepinephrine 
are diminished in BSS treated B4galnt1+/− mice with respect to WT mice (Fig. 8, Fig. S5 of Supplementary). 
Importantly, we found that the levels of DA, DOPAC and of norepinephrine were rescued in OligoGM1 treated 
B4galnt1+/− mice (Fig. 8, Fig. S5 of Supplementary).
Discussion
Unlike familial forms, sPD has no cogent theory that summarizes the disparate data into a compelling narrative 
regarding its etiology42. Although various hypotheses have been suggested, none has successfully reconciled the 
collected data that explain the diverse central and peripheral manifestations of PD. α-Syn is generally considered 
to have a central role in PD, but as yet there is no explanation as to what causes its elevation and resultant aggrega-
tion in sporadic PD coinciding with progressive impairment of the neuronal dopaminergic system12.
Recently, a theory has emerged that defines a central role for ganglioside GM1 which levels diminish with 
aging7,8 and/or under epigenetic influences; it was proposed that in some individuals, presumably those start-
ing life with lower levels, GM1 falls below a threshold level necessary to maintain TH neuron viability thereby 
gradually leading to sPD12. This would be the consequence of the numerous essential neuronal functions of 
GM114,23. Considering the cases reported so far, sPD patients show GM1 deficiency in the substantia nigra9, the 
occipital cortex13, and in various peripheral tissues12, suggesting a systemic GM1 deficiency. Moreover, a signif-
icantly deficient expression in genes involved in ganglioside synthesis (B3GALT4, ST3GAL2) was reported in 
neuromelanin-containing neurons (but not in other neuronal types) in the substantia nigra of sPD subjects10. 
These findings suggest a ganglioside systemic deficiency that would correlate with the systemic symptoms of sPD.
It has been hypothesized that subnormal levels of a-series ganglioside (GM1/GD1a) can gradually compro-
mise several neuronal functions14,23. In particular, the reduced level of plasma membrane GM1 in sPD neurons 
can trigger the neurodegenerative process by a failure in trophic signaling via GDNF13 together with a reduction 
of clearance promoting the α-syn accumulation6,14,43. Most relevant in regard to neurodegeneration are neuro-
trophic factors whose receptors require GM1 association to facilitate lifelong survival of neurons. An example of 
this was the finding that GM1 binds with high-affinity to TrkA, the NGF receptor, and promotes tyrosine auto-
phosphorylation: the starting event leading to neurite elongation34,44–47. Moreover, a similar GM1 partnership 
Figure 2. OligoGM1 effect on motor balance and coordination measured by grip duration test. (A–E) 
B4galnt1+/− mice at 270 days of age were IP injected with 20 mg/kg OligoGM1 (n = 12) or with BSS (n = 12) 
daily for 4 weeks. WT mice (n = 9) of the same age were IP injected with BSS daily for 4 weeks. Data are 
expressed as mean ± SEM [one-way ANOVA followed by Bonferroni’s multiple comparisons test]. (A) Week 0, 
F(2,30) = 31.36, ****p < 0.0001 B4galnt1+/− + BSS and B4galnt1+/− + OligoGM1 compared with WT. (B) Week 
1, F(2,30) = 13.30, ****p < 0.0001 B4galnt1+/− + BSS compared with WT and *p < 0.05 B4galnt1+/− + OligoGM1 
compared with WT. (C) Week 2, F(2,30) = 3.842, *p < 0.05 B4galnt1+/− + BSS compared with WT and 
B4galnt1+/− + OligoGM1. (D) Week 3, F(2,30) = 7.546, **p < 0.01 B4galnt1+/− + BSS compared with WT and 
B4galnt1+/− + OligoGM1. (E) Week 4, F(2,30) = 8.630, **p < 0.01 B4galnt1+/− + BSS compared with WT and 
B4galnt1+/− + OligoGM1; (F) overview of the 4 weeks’ treatment (●WT + BSS; ■ B4galnt1+/− + BSS; ▼ 
B4galnt1+/− + OligoGM1).
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has been reported for the GDNF receptor, comprising RET receptor and GPI-anchored co-receptor GFRα12,13. 
Deficiency of RET phosphorylation, an indicator of failed GDNF signaling, was identified in the substantia nigra 
of sPD subjects and also in the GM1-deficient B4Galnt1+/− mice; in the latter GDNF signaling was restored by 
LIGA20, a membrane-permeable analog of GM113. In addition, GM1 displays binding to the soluble α-syn, and 
the interaction between GM1 and α-syn has been proposed to prevent α-syn aggregation and deposition15,16. 
Structural studies have shown the existence of α-syn region defined as the ganglioside binding region15. In vitro 
experiments revealed that N-alpha-acetylation of α-syn strengthened the interaction with GM1 and its resistance 
to aggregation16. In addition to this, free α-syn inhibits Nurr1, necessary for the expression and functioning of 
Figure 3. OligoGM1 effect on fine motor movement (sensorimotor) measured by irritant removal test. 
(A–E) B4galnt1+/− mice at 270 days of age were IP injected with 20 mg/kg OligoGM1 (n = 12) or with BSS 
(n = 12) daily for 4 weeks. WT mice (n = 9) of the same age were IP injected with BSS daily for 4 weeks. Data 
are expressed as mean ± SEM [one-way ANOVA followed by Bonferroni’s multiple comparisons test]. (A) 
Week 0, F(2,21) = 3.710, *p < 0.05 B4galnt1+/− + BSS and B4galnt1+/− + OligoGM1 compared with WT. (B) 
Week 1, no significant difference between B4galnt1+/− + BSS or + OligoGM1 compared with WT. (C) Week 
2, F(2,19) = 5.256, *p < 0.05 B4galnt1+/− + BSS compared with WT and B4galnt1+/− + OligoGM1. (D) Week 3, 
F(2,30) = 6.783, *p < 0.05 B4galnt1+/− + BSS compared with WT and **p < 0.01 B4galnt1+/− + BSS compared 
with B4galnt1+/− + OligoGM1. (E) Week 4, F(2,19) = 6.027, **p < 0.01 B4galnt1+/− + BSS compared with WT 
and B4galnt1+/− + OligoGM1; (F) overview of the 4 weeks’ treatment (●WT + BSS; ■ B4galnt1+/− + BSS; ▼ 
B4galnt1+/− + OligoGM1).
Figure 4. OligoGM1 effect on motor balance and coordination measured by pole climbing test. B4galnt1+/− 
mice at 270 days of age were IP injected with 20 mg/kg OligoGM1 (n = 12) or with BSS (n = 12) daily for 4 
weeks. WT mice (n = 9) of the same age were IP injected with BSS daily for 4 weeks. Data are expressed as mean 
± SEM: F(2,52) = 10.37, ***p < 0.001 B4galnt1+/− + BSS compared with WT and B4galnt1+/− + OligoGM1 [one-
way ANOVA followed by Bonferroni’s multiple comparisons test].
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GDNF signaling48. Significantly, application of GM1 to a rat α-syn model of PD reduced α-syn aggregation43.
Thus, the reduction of brain GM1 is claimed to be responsible for the onset of sPD.
GM1 replacement therapy has shown modest but significant success in a monocentric controlled, delayed 
start trial in treated sPD patients, acting as symptomatic and potentially disease modifier17; significantly, partial 
restoration of DA transporter functional level in the striatum of GM1-treated subjects was reported18. These 
results strongly support the idea that the loss of GM1-sustained trophism is the crucial point in sPD pathogenesis, 
so much so that restoring its brain level ameliorates symptoms and slows the disease progression. However, the 
great amount of GM1 necessary to obtain results, its animal origin and its discussed immunogenicity22,23 have 
questioned GM1 as a suitable drug for human therapy.
Beneficial results were gained in B4galnt1 GM1-deficient mice treated with a semi-synthetic, brain-permeable 
GM1 ganglioside analog, LIGA209,12,13. This GM1 analogue was prepared by FIDIA-Farmaceutici S.p.a. (Italy) 
as membrane permeable ganglioside analog capable to traverse the blood brain barrier. In those mice, LIGA20 
treatment could also reduce accumulation of α-syn in substantia nigra9,12. Most important in this study is the fact 
that the use of a more hydrophilic GM1 derivative, modified on the ceramide moiety with a dichloroacetyl group 
instead of the C18 acyl chain, but keeping the entire oligosaccharide chain intact, still maintains trophic potential, 
supporting the hypothesis that only specific plasma membrane oligosaccharide–protein triggered pathway is 
required for the correct neuronal homeostasis9,12 and not the lipid moiety. Human therapy based on that particu-
lar compound cannot be approached due to the toxicity of the dichloroacetyl moiety.
Figure 5. Ganglioside content in brain cortex (A) and cerebellum (B). Ganglioside patterns resolved by HPTLC 
in the presence of specific standards and revealed by Ehrlich spray reagent. On the left: HPTLC representative 
image. On the right: relative quantitation of the intensity of each ganglioside band normalized on the protein 
content. Patterns are representative of those obtained for all the animals analyzed (WT, n = 5; B4galnt1+/− + 
BSS, n = 8 B4galnt1+/− + OligoGM1, n = 8). Data are express as fold increase or decrease over WT of mean 
± SEM: (A) GM1: F(2,21) = 23.54 ****p < 0.0001, GD1a: F(2,21) = 18.35 ****p < 0.0001, GD3: F(2,21) = 5.178, 
GD1b F(2,21) = 5.762 *p < 0.05 WT vs B4galnt1+/− (one-way ANOVA, followed by Bonferroni’s post-hoc test); 
(B) GM1: F(2,21) = 6.948 **p < 0.01, GD1a: F(2,21) = 46.01 ****p < 0.0001, GD3: F(2,18) = 5.479 *p < 0.05 WT vs 
B4galnt1+/− (one-way ANOVA, followed by Bonferroni’s post-hoc test).
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It was notable that plasma membrane GM1 increase by intraventricular injection of Vibrio cholerae sialidase 
exerts a neuroprotective effect on the damaged nigrostriatal DA system of MPTP mice49. This enzyme removes 
sialic acid residues from polysialogangliosides (e.g. GD1a) in the brain, thus increasing plasma membrane GM1. 
In this scenario, the idea emerges that plasma membrane GM1 oligosaccharide decline could be the trigger for 
sustained pathways impairment as the etiopathogenetic target event of PD.
Recently, we showed in neuronal cells that, within the entire GM1 molecule, the oligosaccharide chain is the 
actual moiety responsible for GM1 neurotrophic properties35–37. GM1 oligosaccharide directly interacts with 
the NGF receptor TrkA, leading to ERK1/2 downstream pathway activation, to cell differentiation and to sus-
tained neuroprotection from MPTP toxicity. Proteomic analysis revealed a broad spectrum of molecular events 
prompted by the OligoGM1 involving calcium regulation, antioxidant mechanism, mitochondrial bioenergetics, 
and anti-inflammatory response36.
Considering all our in vitro evidence about the OligoGM1 neurotrophic potential, we wondered if the 
OligoGM1 could be used to replace GM1 functions using the B4galnt1+/− mouse as in vivo approach. This model, 
obtained by the heterozygous disruption of the B4galnt1 gene (GM2/GD2 synthase) causing partial deletion of 
GM1, represents an accurate recapitulation of the human sPD condition. These mice, with reduced brain content 
of GM1 and GD1a (especially in the SNpc9) with respect to the WT condition, develop progressively the sPD phe-
notype: alteration of neurotrophic signaling, SNpc α-syn elevation and aggregation within CNS and PNS lesions, 
loss of TH-expressing neurons in the SNpc, striatal degeneration, and increasing motor dysfunction9,12,13,28.
Firstly, we verified the capacity of the OligoGM1 to cross the blood brain barrier and stably reach the CNS, 
postponing a detailed study on its pharmacological distribution to the future. This study demonstrated recovery 
of normal motor function in the B4galnt1+/− mice by OligoGM1 treatment, as shown with three movement 
Figure 6. α-syn content within substantia nigra. On the top: representative fluorescent IHC images of 
α-syn (red) and nuclei (blue) immunolabeling in the SNpc. (1–2) WT + BSS (n = 4); (3–4) B4galnt1+/− + 
BSS, (n = 4) (5–6) B4galnt1+/− + OligoGM1, n = 4). On the bottom: quantification of α-syn normalized on 
nuclei area (n = 4 for group; 8–10 brain sections/animal). Data are expressed as mean ± SEM (F(2,32) = 7.7, 
**p < 0.01 B4galnt1+/− + BSS compared with WT and B4galnt1+/− + OligoGM1; one-way ANOVA followed by 
Bonferroni’s multiple comparisons test).
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tests. Similarly, neuropathological lesions were largely resolved by OligoGM1 in relation to nigral TH-expressing 
neurons and neurotransmitter (DA, norepinephrine) levels in the striatum. OligoGM1-treated animals also 
showed a significant reduction of the abnormal α-syn content compared to untreated animals at the level of 
SNpc. Although we performed a limited examination regarding the toxic phosphorylated form of α-syn, which 
Figure 7. TH expression in the substantia nigra. (A) On the top: representative fluorescent IHC images of 
TH+ neurons (red) and nuclei (blue) immunolabeling in the SNpc. (1–2) WT + BSS (n = 4); (3–4) B4galnt1+/− 
+ BSS, (n = 4) (5–6) B4galnt1+/− + OligoGM1, n = 4). On the bottom: quantification of the TH+ neurons 
normalized on nuclei area (n = 4 for group; 8–10 brain/sections animal). Data are expressed as mean ± SEM 
(F(2,32) = 17.26, ****p < 0.001 B4galnt1+/− + BSS compared with WT and B4galnt1+/− + OligoGM1; one-way 
ANOVA followed by Bonferroni’s multiple comparisons test). (B) On the left: representative immunoblotting 
images of TH and calnexin are shown after cropping (full length images of blot are presented as Supplementary 
Fig. S8). On the right: Semi-quantitative analysis of nigral TH expression related to calnexin level (n = 4). 
Data are expressed as fold increase or decrease over the control (WT) of the mean ± SEM (F(2,8) = 10.34, 
**p < 0.01 B4galnt1+/− + BSS compared with WT and B4galnt1+/− + OligoGM1; one-way ANOVA followed by 
Bonferroni’s multiple comparisons test).
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specifically represents the dominant pathological modification of α-syn in familial and sporadic Lewy body 
diseases, as well as in transgenic animal models of synucleinopathies50–52, we found a reduction expression in 
the α-syn phosphorylation (Ser129) in OligoGM1-treated B4galnt1+/− mice compared to untreated mice. Now, 
follow-up studies are necessary to study in detail the relationship between OligoGM1 administration and α-syn 
phosphorylation and aggregation.
Importantly, we did not find any difference in ganglioside content between OligoGM1 and BSS treated 
B4galnt1+/− mice, suggesting that the OligoGM1 is not able to influence the ganglioside metabolic pathway.
Although our study does not explain the exact mechanism by which the OligoGM1 rescues the PD pheno-
type, it strongly supports the idea that it could account for the GM1 neurotrophic function. Our hypothesis is 
that the sPD pathogenesis is fundamentally due to plasma membrane GM1 deficiency that causes the alteration/
loss of molecular interaction between the oligosaccharide portion of GM1 and specific proteins, giving rise to the 
gradual impairment of several functions. We suggest that in sPD neurons, the reduced level of GM1, and hence 
of its oligosaccharide, could trigger the neurodegenerative process by a failure in trophic signals together with a 
reduction of α-syn clearance.
The idea that the age-dependent GM1 deficiency could be the trigger for idiopathic PD is attractive, not only 
because it is supported by preclinical data, but also because it recognizes that GM1 functions as a key node in a 
network of regulated processes and its deficiency would affect the neuronal homeostasis in multi-modal ways12,14. 
The GM1 decrease could drive trophic signaling failure and α-syn accumulation, leading in turn to glia/microglia 
activation, oxidative stress, mitochondria dysfunction and excitotoxicity, resulting in the onset of cell death. Our 
recent data36 showed that GM1 oligosaccharide activates a broad range of neuroprotective biochemical pathways 
in neuroblastoma cells and prevents their death caused by toxic molecules. The latter findings, together with the 
results of the present work, concur in setting a reasonable basis for considering GM1 oligosaccharide as an agent 
that overcomes GM1 pharmacological limits and could display significant therapeutic benefit for sPD.
Materials and Methods
Materials. Commercial chemicals were of the highest purity available, common solvents were distilled before 
use and water was doubly distilled in a glass apparatus.
Paraformaldehyde (PFA), BSS, sucrose, fetal calf serum, Triton X-100, bovine serum albumin, trypan blue, 
perchloric acid, sodium acetate, sodium octyl sulfate, EDTA, DA, DOPAC and DAPI were from Sigma-Aldrich 
(St. Louis, MO, USA). Phosphate buffered saline (PBS) was from EuroClone. 4–20% Mini-PROTEAN TGX 
Precast Protein Gels, Turbo Polyvinylidene difluoride (PVDF) Mini-Midi membrane and DC protein assay kit 
were from Bio-Rad (Hercules, CA, USA). HPTLC plates were from Merck (Frankfurt, Germany). Optima cutting 
temperature (OCT) was from VWR (Radnor, PA, USA). Dako fluorescent mounting medium was from Dako 
(Glostrup, Denmark). Chemiluminescent kit for western blot was from Cyanagen (Bologna, Italy). Ultima gold 
was from PerkinElmer (Waltham, MA, USA).
GM1 ganglioside and GM1 oligosaccharide preparation. GM1 ganglioside was purified from the 
total ganglioside mixture extracted from fresh pig brains collected at the slaughterhouse of the Galbani company 
(Melzo, Italy), according to the procedure developed previously53. The ganglioside mixture, 5 g as sialic acid, was 
dissolved in prewarmed (36 °C) 500 mL of 0.05 M sodium acetate, 1 mM CaCl2 buffer, pH 5.5. Vibrio cholerae 
sialidase (1 unit) was added to the solution every 12 h54. Incubation at 36 °C and under magnetic stirring was 
maintained for two days, and the solution dialyzed at 23 °C for 4 days against 10 L of water changed 5 times a day. 
The sialidase treated ganglioside mixture was subjected to 150 cm × 2 cm silica gel 100 column chromatography 
equilibrated and eluted with chloroform-methanol-water, 60:35:5 by vol. The fractions containing GM1, identi-
fied by TLC, were pooled, dried and submitted to a further column chromatographic purification using the above 
experimental conditions. Fractions containing pure GM1 were collected and dried. The residue was dissolved in 
Figure 8. Striatal neurotransmitter content. (A,B) Striatal tissue DA and DOPAC content are expressed as 
pico-grams per mg of wet weight of tissue. Data are expressed as mean ± SEM: DA, F(2,9) = 4.61, *p < 0.05 
B4galnt1+/− + BSS compared with WT and B4galnt1+/− + OligoGM1; DOPAC, F(2,9) = 4.834, *p < 0.05 
B4galnt1+/− + BSS compared with WT and B4galnt1+/− + OligoGM1 (n = 4, one-way ANOVA followed 
by Bonferroni’s multiple comparisons test). (C) Striatal tissue norepinephrine content data are expressed as 
arbitrary units (mvolt). Data are expressed as mean ± SEM (n = 4, F(2,9) = 4.915, *p < 0.05 B4galnt1+/− + 
BSS compared with WT and B4galnt1+/− + OligoGM1; one-way ANOVA followed by Bonferroni’s multiple 
comparisons test).
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chloroform-methanol (2:1 v/v) and precipitated by adding 4 volumes of cold acetone. After centrifugation (15,000 
× g) the GM1 pellet was separated from the acetone, dried, dissolved in 50 mL of deionized water and lyophilized 
giving 1350 mg of white powder which was stored at −20 °C.
GM1 containing tritium at position 6 of external galactose was prepared by enzymatic oxidation with galac-
tose oxidase followed by reduction with sodium boro[3H]hydride55.
The oligosaccharides II3Neu5Ac-Gg4 and II3Neu5Ac-[6-3H(IVGal)]Gg4 (OligoGM1 and [3H]OligoGM1, 
respectively) were prepared by ozonolysis followed by alkaline degradation56 of GM1 and [3H]GM1, respectively. 
Minor changes for the alkaline degradation were introduced. Briefly, GM1 ganglioside or [3H]GM1 gangliosides 
was dissolved in the minimum required methanol and slowly saturated with and maintained under ozone at 
23 °C for 6 h under continuous stirring. The solvent was then evaporated under vacuum and the residue brought 
immediately to pH 10.5–11.0 by addition of triethylamine. After solvent evaporation, GM1 oligosaccharide or 
[3H]GM1 oligosaccharide was purified by flash chromatography using chloroform/methanol/2-propanol/water 
60:35:5:5 v/v/v/v as eluent. GM1 oligosaccharide was dissolved in methanol and stored at 4 °C.
NMR, Mass Spectrometry and HPTLC analyses showed a purity over 99% for the prepared OligoGM1 (Fig. S6 
of Supplementary Files). HPTLC followed by radio-imaging showed a purity over 98% for the [3H]OligoGM1 
(Fig. 1B).
Animal. All animal procedures were approved by the Rutgers University and conducted in accordance with 
Institutional Animal Care and Use Committee guidelines. Mice were handled following the Ethical Guidelines for 
Treatment of Laboratory Animals of Rutgers University.
Animals were housed with a 12 h light/12 h dark cycle in groups of five in plastic cages with ad libitum access 
to food and water.
A breeding pair of heterozygotes with disrupted gene for B4galnt1 (C57BL/6 background), created by Dr. 
Richard Proia and coworkers57, was provided as gift by Dr. Ronald Schnaar (Johns Hopkins University, Baltimore, 
MD, USA). Generation of B4galnt1+/− − C57BL/6 J heterozygous mice has been described previously9. All mice 
were backcrossed for 10 generations in a C57BL/6J background. For all experiments, WT mice with the same 
genetic background bred and housed in the same animal facility were used as controls. All mice were 8–9 months 
old at the start of the experiments. Animals were genotyped as previously reported58. Both male (35 to 45 g) and 
female (25 to 35 g) mice have been included in the study to maintain the variability introduced by sex factors, 
reported for PD59.
Animals treatment. OligoGM1 was dissolved in BSS at a concentration of 4 mg/mL and was injected intra-
peritoneal (IP) at 20 mg/kg body weight, daily for 4 weeks.
Since it is already known that systemically administered GM1 fails to cross the blood brain barrier60, in our 
experiments we chose an arbitrary and lower dose of the oligosaccharide molecule with respect to the quantity of 
the lipid (GM1) used in peripheral neurodegenerative experiments in the past (30 mg/kg)61.
B4galnt1+/− mice were randomly assigned to receive daily BSS (n = 12, female n = 6, male n = 6) or OligoGM1 
(n = 12, female n = 6, male n = 6). No animal was excluded from analysis. At the conclusion of the study (treat-
ment and parallel behavioral testing), animals were euthanized, and randomly divided for the biochemical 
analysis.
For IHC analysis, four brain for each group [WT + BSS n = 4 (2 male and 2 female); B4galnt1+/− + BSS n = 4 
(2 male and 2 female); B4galnt1+/− + OligoGM1, n = 4 (2 male and 2 female)] were fixed in 4% PFA. For neu-
rochemical, ganglioside and western blotting studies the same animals were used to collect different brain area. 
Specifically:
•	 for neurochemical analysis striatal samples (both sides) were rapidly removed and immediately frozen for 
later analysis from four brain for each group [WT + BSS n = 4 (2 male and 2 female); B4galnt1+/− + BSS n = 4 
(2 male and 2 female); B4galnt1+/− + OligoGM1 n = 4 (2 male and 2 female)].
•	 for ganglioside analysis, cortex and cerebellum samples were rapidly collected and immediately frozen 
for later analysis [WT + BSS n = 5 (3 male and 2 female), B4galnt1+/− + BSS n = 8 (4 male and 4 female), 
B4galnt1+/− + OligoGM1, n = 8 (4 male and 4 female)];
•	 for western blotting substantia nigra samples were rapidly removed and immediately frozen for later analysis 
from four brain for each group [WT + BSS n = 4 (2 male and 2 female); B4galnt1+/− + BSS n = 4 (2 male and 
2 female); B4galnt1+/− + OligoGM1 n = 4 (2 male and 2 female)].
Behavioral experimental procedures. The sample size was predetermined using G*Power software and 
a priori analysis9,28. The effect size was determined for each experiment considering the difference we expected 
to see with respect to control group and the standard deviations that we derived from previous published data. 
Before starting behavioral experiments, each animal was handled for five days. Each experiment was performed 
during the light cycle and in a separate behavioral testing room after a 30-min-period of acclimation. During the 
test performing the rater was blind as to the experimental condition of the animal.
Grip duration test was used to test motor coordination and balance38. Briefly, each mouse was suspended by 
its forepaws on a horizontal rounded metal bar (diameter 3 mm) positioned 50 cm above a foam pillow and the 
mouse’s tail is gently held by experimenter to prevent climbing with hind legs9,13,62. The hang time to fall is meas-
ured up to 600 s for each trial in three consecutive trials, with a rest interval of 30 min. The hang times were then 
averaged for each mouse. Mice were tested for grip duration before starting the treatment to measure the basal 
state and once a week over the treatments.
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Irritant removal test was assessed to determine motor response to sensory stimulus9,13,38,63. Each mouse is 
restrained and a small piece of adhesive is applied on the snout using forceps. The mouse is placed in a cage and 
a timer is set to record how long it takes each mouse to remove the sticker, typically with their forepaws. The 
maximum amount of time each mouse is tested is 2 min (120 s), and if a mouse fails to remove the sticker it scores 
120 s. The testing was performed over 5 trials with mice having a short break between trials and mean of times 
were considered for subsequent analyses. The base line was measured before starting the OligoGM1 administra-
tion and, throughout treatment mice were weekly tested.
Pole climbing test was used to test motor coordination and balance9,13,38. A wooden pole (diameter 8 mm, 
height 55 cm) was tilted at 45° angle with respect to the floor. The times spent by each mouse to ascend, turn 
around and descend the pole is measured. Mice were trained two times 2 hours before the test to allow familiar-
ization with the equipment. Mice were tested three times and the times were averaged for each mouse. The pole 
climbing test was performed at day 27 of treatment, to prevent learning from compromising the success of the 
test.
Neurochemical analysis. The levels of DA, DOPAC and norepinephrine were determined by measuring 
their tissue content in the striatum of animals after 4 weeks of treatment as previously reported64,65. Briefly, mice 
were anesthetized with IP injection of ketamine (100 mg/kg)/xylazine (10 mg/kg), and were decapitated. Striatal 
tissue was rapidly dissected on ice, weighed and frozen at −80 °C for future analysis. Upon thawing, each stri-
atum sample (both side) was homogenized on ice with a mechanical stirrer (Mechanical Stirrer – Heavy duty, 
ISOLAB, Laborgerate GmbH, electronic speed settled at 300 rpm) for 30 sec in 0.1 M perchloric acid and 100 μM 
EDTA (20 μL/mg wet tissue). Homogenates were centrifuged at 14,000 × g for 20 min. Catecholamine content 
(sample vol. = 20 μL) of the resulting supernatants were quantified by HPLC–ED. The HPLC-ED system used 
was HTEC-500 (EiCOM USA, San Diego, CA, USA) that was equipped with a reverse-phase column (Varian, 
Brownlee, RP-18, Velosep, 3 μm, C18, 100 Å), and graphite working electrode (WE-3G, EiCOM USA, San Diego, 
CA, USA). Neurotransmitters were separated on a Velosep RP-18 column (100 × 3.2 mm; Applied Biosystems, 
Inc., Foster City, CA, USA) and quantified by measuring oxidative current at a glassy carbon wall-jet electrode 
(WE-GC model; Amuza Neuroscience) set at + 400 mV versus an Ag/AgCl electrode coupled to a potentiostat 
(RE-500; Amuza Neuroscience). The mobile phase consisted in 0.1 M sodium acetate buffer, pH 4.2, 0.1 mM 
EDTA, 1.2 mM sodium octyl sulfate, 8.0% (v/v) methanol. A solvent delivery pump (model HTEC-510; Amuza 
Neuroscience) delivered the mobile phase at 0.7 mL/min. Retention time was used to identify elements of interest, 
which were quantified on the basis of the peak height of oxidative current. The detection limit of the assay was 
0.7 pg DA/sample.
Fluorescent immunohistochemistry (IHC), imaging and analysis. Mice were deeply anesthetized 
with IP injection of ketamine (100 mg/kg)/xylazine (10 mg/kg), and transcardially perfused with 0.1 M PBS 
(23 °C, pH 7.4), followed by freshly prepared ice-cold 4% PFA in PBS. Whole brains were isolated, post-fixed over-
night in 4% PFA at 4 °C and soaked in cryoprotective solution (30% sucrose in PBS) until tissue sinking. Brains 
were snap frozen in pre-cooled isopentane upon OCT embedding and stored at −80 °C, prior to cryostat section-
ing. Tissues were sectioned (16 μm) using cryostat (MC 5050 Semi-automatic Cryostat, Histo-Line Laboratories) 
after OCT compound embedding in dry ice. Sections through the rostro-caudal extent of the substantia nigra 
were collected and every fifth section from substantia nigra was processed for TH and α-syn IHC analysis. SNpc 
was used for the IHC detection of TH and α-syn, as specifically showed in Fig. 7S of Supplementary Files. For 
immunofluorescence, 16 μm slices were treated for 1 h with citrate buffer and heat in a water bath at 80 °C. Then 
the slices were put in a blocking solution (1 h, 23 °C) containing 10% fetal calf serum and 0.25% Triton X-100 in 
PBS. After blocking, samples were incubated with the primary antibody diluted with the same solution overnight 
at 23 °C. The slices were then incubated with the secondary antibody (1 h, 23 °C), followed by nuclei staining with 
DAPI66 (1:5000, 15 min, 23 °C).
Primary antibodies for the following epitopes were used: anti-TH Rabbit pAb (1:500; Merck Millipore 
Cat# 657012-100UL, RRID:AB_10681344), and anti-α-syn Mouse IgG1 (1:1000; BD Biosciences Cat# 610787, 
RRID:AB_398108). The following secondary antibodies were used: goat anti-Rabbit IgG (H + L) antibody (1:500; 
Alexa Fluor 488, Thermo Fisher Scientific Cat# A-11008, RRID:AB_143165) and goat anti-Mouse IgG1 antibody 
(1:500; Alexa Fluor 568, Thermo Fisher Scientific Cat# A-21124, RRID:AB_2535766).
Confocal images were acquired using a Leica TCS SP5 laser scanning confocal microscope (Leica 
Microsystems, GmbH) using a HCX PL APO 40× (NA 1.25) Oil immersion objective. Tiff images were then 
imported and analyzed using ImageJ software (ImageJ, NIH http://rsb.info.nih.gov/ij/).
Immunoblotting analysis. Freshly collected brains from PBS perfused mice were employed and the mid-
brain cut into 250 μm coronal sections with a vibratome sectioning system in cold PBS. The entire substantia 
nigra region, including pars compacta and reticulata, was isolated by dissecting under the microscope. The pooled 
sections were extracted with 1 mL/100 mg tissue of Cell Lysis Buffer (Cell Signaling, Danvers, MA). Aliquots 
containing 30 μg protein were denatured with Laemmli sample buffer (final concentration 0.1 M DTT, 63 mM 
Tris-HCl, 10% glycerol v/v, 2% SDS w/v, 0.01% blue bromophenol v/v), boiled at 100 °C for 5 min, separated on 
4–20% polyacrylamide gels, and transferred to PVDF membranes using the Trans-Blot Turbo Transfer System 
(Bio-Rad). PVDF membranes were blocked with 5% milk (w/v) in TBS-0.1% tween (v/v) at 23 °C for 1 hour 
under gently shaking. TH and calnexin levels were assayed incubating the PVDF membranes respectively with 
primary anti-TH mouse antibody (1:2000 in 5% milk (w/v) in TBS-0.1% tween (v/v); Santa Cruz Biotechnology 
Cat# sc-25269, RRID:AB_628422), and anti-calnexin mouse antibody (1:1000 in 5% BSA (w/v) in TBS-0.1% 
tween (v/v), BD Biosciences Cat# 610524, RRID:AB_397884) overnight at 4 °C under gently shaking. Following, 
the reaction with secondary HRP-conjugated goat anti-mouse IgG (H + L) antibody (1:2000 in 5% milk (w/v) in 
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TBS-0.1% tween (v/v), Thermo Fischer Scientific, Cat# RRID: AB_228307) at 23 °C for 1 in agitation and luminol 
detection (Cyanagen) were performed. Finally, the TH signal was normalized to calnexin signal. The data acqui-
sition and analysis were performed using Alliance Uvitec (Cleaver Scientific Ltd, UK).
Ganglioside analysis. Cortex and cerebellum were collected from WT and B4galnt1+/− mice treated with 
BSS or OligoGM1 and subjected to lyophilization. The extraction of total lipids from lyophilized tissue was car-
ried out with the solvent system chloroform/methanol/water in proportion of 20:10:1 by vol (1.5 mL/50 mg dry 
tissue) mixing samples at 23 °C in a thermomixer (Eppendorf) at 1400 rpm for 15 min. Total lipid extract was 
separated from the pellet by centrifugation at 13000 × g for 15 min, followed by a second and third extractions 
with chloroform/methanol, 2:1 by vol39–41,67. Total lipid extracts were subjected to a two phase partitioning by 
adding 20% water resulting in the separation of an aqueous phase containing gangliosides and in an organic phase 
containing all the other lipids after centrifugation at 13000 × g for 15 min at 23 °C68. Following a dialysis step to 
remove salts, gangliosides contained in the dialyzes aqueous phase, corresponding to 300 μg of tissue proteins, 
were resolved by mono-dimensional HPTLC using the solvent system chloroform/methanol/0.2% calcium chlo-
ride 50:42:11 by vol69–72. Following solvent evaporation, gangliosides were recognized by specific detection spray-
ing with Ehrlich reagent, which is specific for sialic acid, and heating at 120 °C for 15 min. The relative amount 
of each ganglioside, taking into account its sialic acid content, was determined by densitometry using ImageJ 
software (NIH, Bethesda, USA; http://rsbweb.nih.gov/ij/).
[3H]OligoGM1 penetration into the brain. To assesses the capability of OligoGM1 to reach the brain, 
five WT mice (n = 5, male) weighing 25 g each were IP injected with [3H]OligoGM1 (specific radioactivity: 2.2 Ci/
mmol). A total of 6.5 × 107 dpm of [3H]OligoGM1 was gently dried under nitrogen and dissolved in BSS contain-
ing 2.5 mg of cold OligoGM1. Each mouse was injected with 1.3 × 107 dpm of [3H]OligoGM1 and 0.5 mg of cold 
OligoGM1 corresponding to 20 mg/Kg of OligoGM1. Following 24 h from the injection, animals were euthanized 
by heart perfusion with saline solution to remove the blood73. Immediately the brain, without cerebellum, was 
collected, weighted (±350 mg) and homogenized with 1.4 mL of cold distilled water (rescue 100 mg/400 mL) by 
1 min treatment with a mechanical stirrer (Mechanical Stirrer – Heavy duty, Isolab, Laborgerate GmbH, elec-
tronic speed settled at 1200 rpm) at 4 °C (cold room).
Determination of radioactivity. Brain homogenates were submitted to determination of radioactivity by liquid 
scintillation counting. Specifically, 100 μL of brain homogenate were combined with 5 mL of ULTIMA GOLD 
liquid (PerkinElmer), shaken and counted for 20 minutes by Liquid Scintillation Analyzer (TRI-CARB 2100TR, 
Packard). For each brain homogenate three samples were counted (n = 3). Counting of tritium was carried with a 
program calculating the ratio of counts between two regions of energy spectrum to detect spectral shift and thus 
quenching. In the case of tritium, the regions are typically set from 0 to 18.6 keV in Region A (counting cpm A) 
and 2 to 18.6 in Region B (counting cpm B). Based on the efficiency of the instrument, usually around 70%, cpm 
A and cpm B are converted automatically (by a mathematic integration) into dpm. In our case the efficiency of the 
instrument is 63.09% (H3 eff 0–18.6 keV) and cmp were transformed to dpm according to the curve determined 
with unquenched standard (#6008500/1215–111) provided by PerkinElmer. The radioactivity background was 
automatically subtracted from each sample using as a blank the brain homogenate from an untreated animal.
The value of the radioactivity determined in such way corresponded to volatile and non-volatile radioactivity 
(total radioactivity)73. To establish the specific amount of volatile and non-volatile radioactivity 100 μL of brain 
homogenate (3 samples from each brain, n = 3) were dried under nitrogen flux and resuspended in the same 
initial volume of cold distilled water (100 μL) and counted for radioactivity content as above. The difference 
between the value obtained from non-dry homogenate (total radioactivity) and dry homogenate corresponded 
to non-volatile radioactivity (Fig. S1 of Supplementary).
We recall that the OligoGM1 is tritium labeled at position 6 of external galactose. Any possible galactosi-
dase activity can result in external galactose removal leading to loss of radioactivity from the penta-saccharide. 
Radiolabeled galactose may enter in hepatocytes and may be transformed into glucose. This latter enters in the 
glycolysis pathway finally producing tritiated water. We cannot exclude that a very minor portion of released 
galactose enters in glycoconjugate biosynthesis, but the largest part of non-volatile radioactivity corresponds to 
the original oligosaccharide, while the largest part of volatile radioactivity corresponds to water.
Metabolic stability. To verify that the non-volatile radioactivity indeed correspond to OligoGM1, 600 μL of the 
homogenized mixture was centrifuged at 12000 × g for 10 min at 4 °C and the supernatant containing the sol-
uble fraction was lyophilized. The precipitate was solubilized in 600 μl of distilled water and counted for radi-
oactivity content liquid scintillation counting as above. The lyophilized material was suspended in 600 μL of 
methanol. 60 μL of the methanol solution (1/10 of the starting material) was separated by HPTLC using the 
solvent system chloroform/methanol/0.2% calcium chloride 30:50:13 (v/v/v). The [3H]OligoGM1 was visualized 
with Beta-Imager 2000 instrument (Biospace) using an acquisition time of 16 h and identified using pure [3H]
OligoGM1 as standard.
Protein determination. Protein concentration of samples was assessed using a DC protein assay kit accord-
ing to manufacturer’s instructions, using bovine serum albumin as standard74.
Statistical analysis. Data are expressed as mean ± SEM and were analyzed for significance by one-way or 
two-way ANOVA test followed by Bonferroni’s multiple comparisons post-hoc test. The analysis was performed 
with Prism software (GraphPad Software v8, Inc. La Jolla, CA, USA). In all cases statistical significance was set at 
p < 0.05. All data are available upon request.
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Other analytical methods. NMR spectra were recorded with a Bruker AVANCE-500 spectrometer at a 
sample temperature of 298 K. NMR spectra were recorded in CDCl3 or CD3OD and calibrated using the tri-
methylsilyl signal as internal reference.
Ganglioside and oligosaccharide mass spectrometry analyses were performed in positive ESI-MS. MS spec-
tra were recorded on a Thermo Quest Finnigan LCQTM DECA ion trap mass spectrometer, equipped with a 
Finnigan ESI interface; data were processed by Finnigan Xcalibur software system (Thermo Fisher Scientific, 
Waltham, MA, USA).
All reactions were monitored by HPTLC on silica gel 60 plates.
Data availability
The datasets generated and analyzed during the current study are available from the corresponding authors on 
reasonable request.
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